Page 39 - Caredx Inc News Today

Russell Investments Group Ltd. lowered its position in shares of CareDx, Inc (NASDAQ:CDNA – Get Rating) by 63.8% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,706 shares of the company’s stock after selling 38,181 shares during the period. Russell Investments […]

Symposium, “Improved Precision with a Multimodality Approach,” Reviews Innovative Solutions for a More Holistic View of Allograft Health...

SOUTH SAN FRANCISCO, Calif., April 06, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare

/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Natera, Inc. ("Natera" or the "Company") (NASDAQ: NTRA). Such investors are...

Press release content from NewMediaWire. The AP news staff was not involved in its creation.

SOUTH SAN FRANCISCO, Calif., March 30, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) - The Transplant Company focused on the discovery, development, and commercialization of clinically differentiated

SOUTH SAN FRANCISCO, Calif., March 30, 2022 -- CareDx, Inc. – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated,... | March 30, 2022

Analysts forecast that CareDx, Inc (NASDAQ:CDNA – Get Rating) will post earnings per share (EPS) of ($0.04) for the current quarter, Zacks reports. Three analysts have made estimates for CareDx’s earnings. CareDx posted earnings per share of $0.14 during the same quarter last year, which would indicate a negative year over year growth rate of […]

Represents World’s First Surveillance Solutions for Investigational Use in Xenotransplantation Research and Post-Xenotransplant Clinical Monitoring...

New Features Aim to Help More Patients with Kidney Failure Receive an Organ Transplant...